Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse.

Autor: Chen M; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Mainardi S; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Lieftink C; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands; NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Velds A; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Rink I; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Yang C; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Kuiken HJ; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands; NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Morris B; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands; NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Edwards F; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Jochems F; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., van Tellingen O; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Boeije M; Mouse Clinic for Cancer and Aging Research, Preclinical Intervention Unit, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands., Proost N; Mouse Clinic for Cancer and Aging Research, Preclinical Intervention Unit, The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands., Jansen RA; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Qin S; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Jin H; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Koen van der Mijn JC; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Schepers A; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Venkatesan S; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Qin W; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China., Beijersbergen RL; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands; NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Wang L; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands; State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: l.wang@nki.nl., Bernards R; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: r.bernards@nki.nl.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2024 Mar 19; Vol. 5 (3), pp. 101471.

CD4 ⁺ helper T cells endow cDC1 with cancer-impeding functions in the human tumor micro-environment.

Autor: Lei X; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.; Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands., Khatri I; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands., de Wit T; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.; Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands., de Rink I; Genomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Nieuwland M; Genomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kerkhoven R; Genomics Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Eenennaam H; Aduro Biotech Europe B.V, Oss, The Netherlands., Sun C; Immune Regulation in Cancer, German Cancer Research Center, Heidelberg, Germany., Garg AD; Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium., Borst J; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands. j.g.borst@lumc.nl.; Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands. j.g.borst@lumc.nl., Xiao Y; Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands. y.xiao@lumc.nl.; Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands. y.xiao@lumc.nl.

Publikováno v: Nature communications [Nat Commun] 2023 Jan 13; Vol. 14 (1), pp. 217. Date of Electronic Publication: 2023 Jan 13.

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

Autor: Linder S; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hoogstraat M; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Stelloo S; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Eickhoff N; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Schuurman K; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Barros H; Division of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Alkemade M; Core Facility Molecular Pathology and Biobanking, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Bekers EM; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Severson TM; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Sanders J; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Huang CF; Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada., Morova T; Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada., Altintas UB; School of Medicine, Koç University, Istanbul, Turkey.; Koç University Research Centre for Translational Medicine (KUTTAM), Koç University, Istanbul, Turkey., Hoekman L; Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kim Y; Department of Pathology, Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam, the Netherlands., Baca SC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; The Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Sjöström M; Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Zaalberg A; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Hintzen DC; Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Jong J; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Kluin RJC; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., de Rink I; Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Giambartolomei C; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Seo JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Pasaniuc B; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.; Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California., Altelaar M; Proteomics Facility, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht Institute for Pharmaceutical Sciences, Utrecht University and Netherlands Proteomics Centre, Utrecht, the Netherlands., Medema RH; Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Feng FY; Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.; Department of Urology, University of California, San Francisco, San Francisco, California., Zoubeidi A; Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada., Freedman ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; The Eli and Edythe L. Broad Institute, Cambridge, Massachusetts., Wessels LFA; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Faculty of EEMCS, Delft University of Technology, Delft, the Netherlands., Butler LM; Freemasons Centre for Male Health and Wellbeing, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.; South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia., Lack NA; Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada.; School of Medicine, Koç University, Istanbul, Turkey.; Koç University Research Centre for Translational Medicine (KUTTAM), Koç University, Istanbul, Turkey., van der Poel H; Division of Urology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Urology, Amsterdam University Medical Centers, Amsterdam, the Netherlands., Bergman AM; Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Zwart W; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.

Publikováno v: Cancer discovery [Cancer Discov] 2022 Sep 02; Vol. 12 (9), pp. 2074-2097.

Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance.

Autor: Gawi Ermi, Ali¹ (AUTHOR) ali.gawiermi@vcuhealth.org, Sarkar, Devanand² (AUTHOR) devanand.sarkar@vcuhealth.org

Publikováno v: Cancers. Dec2024, Vol. 16 Issue 23, p3944. 30p.

Exploring COX-Independent Pathways: A Novel Approach for Meloxicam and Other NSAIDs in Cancer and Cardiovascular Disease Treatment.

Autor: Cheng, Lixia¹ (AUTHOR) chenglixia99@163.com, Hu, Zhenghui¹ (AUTHOR) huzhenghui88@163.com, Gu, Jiawei² (AUTHOR) jiawku17@gmail.com, Li, Qian¹ (AUTHOR) 15736745922@163.com, Liu, Jiahao¹ (AUTHOR) liujiahao4035@163.com, Liu, Meiling¹ (AUTHOR) 13517180571@163.com, Li, Jie¹ (AUTHOR) L364210lijie@163.com, Bi, Xiaowen¹ (AUTHOR) bixiaowen90@ncu.edu.cn

Publikováno v: Pharmaceuticals (14248247). Nov2024, Vol. 17 Issue 11, p1488. 21p.